+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
ID07604311

Randomized, Double-blind Study of Nefecon 8 mg Daily to Prevent Relapse in IgA Nephropathy Patients After Proteinuria Remission

Led by Nanfang Hospital, Southern Medical University · Updated on 2026-09-02

288

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

IgA nephropathy IgAN is a chronic kidney disease where controlling proteinuria and preventing relapse are important to slow disease progression. This trial evaluates the use of Nefecon 8 mg as a maintenance therapy over 15 months in patients who have achieved proteinuria remission after previous treatment, aiming to reduce the risk of relapse. The study is a randomized, double-blinded, placebo-controlled Phase 4 trial focused on treatment of IgAN. Participants are randomly assigned to receive either Nefecon 8 mg or a placebo once daily by mouth for 15 months. The study compares these two groups to assess the efficacy and safety of continued Nefecon treatment after an initial longer course. Patients must have completed at least 9 months of Nefecon 16 mg before starting this maintenance phase, and their proteinuria levels must be low at screening. During the study, participants will have regular assessments including measurements of kidney function, proteinuria levels, and adverse events over the 15-month treatment period. The main outcome is the time to first disease relapse, with additional measures including kidney filtration rate changes, proteinuria levels, major kidney events, and mortality. The trial also monitors safety and overall health throughout the study duration.

CONDITIONS

Brief Title

Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy

Research Team

F

Fan Fan Hou

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here